Search Results

Heightened diligence standards and longer decision timelines for early-stage startups slowed venture activity last year, J.P. Morgan found in a report published ahead of the bank’s annual healthcare conference in San Francisco.

The prevalence of serious inflammatory safety issues such as cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome limits the reach of these transformative cancer therapies.

After greenlighting 56 novel therapeutics in 2025, four notable applications continue to await the agency’s action after being delayed from the fourth quarter last year.

After years stuck in the “doldrums,” the biopharma sector is in a “very good place” heading into the new year, analysts told BioSpace, with both rare and chronic diseases headlining investor and R&D interest as JPM26 kicks off.

Join BSI Consulting’s “Better Together: A Pharma & Biotech EHS Forum” at Boston’s Museum of Science on February 25, 2026! This one-day forum brings together EHS leaders and professionals across the pharmaceutical and biotech fields for a focused exchange on shared EHS challenges. Attendees will learn about the operational impact of misclassified waste, identify gaps in biosafety implementation, explore practical applications of AI, and address workforce competency challenges. Reserve your spot today!

Company to Highlight the complete solution to the GLP-1 weight regain crisis: Only All-Oral Dual-Mechanism Metabolic Platform in Clinical Development, Featuring First-in-Class Oral GLP-1 Agonist and Muscle-Selective AMPK Activator

Insmed’s freshly approved lung condition drug soared past sales expectations for 2025, netting $144.6 million in its first full quarter of sales.